Evidence map›Paper›PMID 34168409›Full record

ArticleWorld journal of gastroenterology2021

Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease.

Jie Zhou, Yang Yang, Yi-Ling Wang, Yue Zhao, Wen-Jing Ye, Si-Yao Deng, Jin-Yi Lang, Shun Lu

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. The roles of EZH2 in cancer and its inhibitors.Medical oncology (Northwood, London, England) · 2023
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jie ZhouDepartment of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China.
Yang YangDepartment of Oncology, The Third People's Hospital of Chengdu, Chengdu 255415, Sichuan Province, China.
Yi-Ling WangDepartment of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China.
Yue ZhaoDepartment of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China.
Wen-Jing YeDepartment of School of Medicine, University of Electronic Science and Technology of China, Chengdu 397992, Sichuan Province, China.
Si-Yao DengDepartment of School of Medicine, University of Electronic Science and Technology of China, Chengdu 397992, Sichuan Province, China.
Jin-Yi LangDepartment of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China.
Shun LuDepartment of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China.
Sichuan Cancer Hospital · CNUniversity of Electronic Science and Technology of China · CNThird People's Hospital of Chengdu · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) is a prevalent worldwide health problem featured by relapsing, chronic gastrointestinal inflammation. Enhancer of zeste homolog 2 (EZH2) is a critical epigenetic regulator in different pathological models, such as cancer and inflammation. However, the role of EZH2 in the IBD development is still obscure.

aimTo explore the effect of EZH2 on IBD progression and the underlying mechanism.

methodsThe IBD mouse model was conducted by adding dextran sodium sulfate (DSS), and the effect of EZH2 on DSS-induced colitis was assessed in the model. The function of EZH2 in regulating apoptosis and permeability was evaluated by Annexin V-FITC Apoptosis Detection Kit, transepithelial electrical resistance analysis, and Western blot analysis of related markers, including Zona occludens 1, claudin-5, and occludin, in NCM460 and fetal human colon (FHC) cells. The mechanical investigation was performed by quantitative reverse transcription

resultsThe colon length was inhibited in the DSS-treated mice and was enhanced by the EZH2 depletion in the system. DSS treatment caused a decreased histological score in the mice, which was reversed by EZH2 depletion. The inflammatory cytokines, such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, were induced in the DSS-treated mice, in which the depletion of EZH2 could reverse this effect. Moreover, the tumor necrosis factor-α treatment induced the apoptosis of NCM460 and FHC cells, in which EZH2 depletion could reverse this effect in the cells. Moreover, the depletion of EZH2 attenuated permeability of colonic epithelial cells. Mechanically, the depletion of EZH2 or EZH2 inhibitor GSK343 was able to enhance the expression and the phosphorylation of janus kinase 2 (JK2) and signal transducer and activator of transcription in the NCM460 and FHC cells. Specifically, EZH2 inactivated JAK2 expression by regulating histone H3K27me3. JAK2 inhibitor TG101348 was able to reverse EZH2 knockdown-mediated colonic epithelial cell permeability and apoptosis.

conclusionThus, we concluded that EZH2 contributed to apoptosis and inflammatory response by inactivating JAK2/ signal transducer and activator of transcription signaling in IBD. EZH2 may be applied as a potential target for IBD therapy.

Indexed as

ColitisEnhancer of Zeste Homolog 2 ProteinInflammatory Bowel DiseasesJanus Kinase 2STAT Transcription FactorsAnimalsApoptosisDextran SulfateDisease Models, AnimalHumansMiceDextran SulfateEnhancer of Zeste Homolog 2 ProteinJanus Kinase 2STAT Transcription FactorsApoptosisEnhancer of zeste homolog 2Inflammatory bowel diseaseInflammatory bowel disease therapyJAK2Permeability

Identifiers

PMID34168409
PMCPMC8192283
OpenAlexW3169477546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.